HepQuant LLC and The University of Colorado have completed a licensing agreement that allows HepQuant to continue development of a CU diagnostic technology for evaluating liver disease. The Colorado-based company originally licensed the technology in 2008 when it also received a $100,000 seed grant from the CU Technology Transfer Office. The underlying technology for the diagnostic was invented by Gregory Everson, Professor and Director of Hepatology at the UC Denver School of Medicine. The first product in development based on this technology is HepQuant-Dual, which is a non-invasive test to measure the liver’s portal circulation using natural compounds labeled with stable isotopes. Information on portal circulation will help physicians detect liver disease and assess its severity and the risk of future complications. The company expects to begin clinical trials of its first product late this year.